VERTEX PHARMACEUTICALS INC / MA
For the period ended Jun 30, 2026. Filed Aug 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 4, 2026
What changed in Risk Factors?
Read the current filingPrevious report: 10-Q
Period ended 2026-03-31; filed 2026-05-05.
0000875320-26-000173
Item 1A. Risk FactorsCurrent report: 10-Q
Period ended 2026-06-30; filed 2026-08-04.
0000875320-26-000259
Item 1A. Risk FactorsThe baseline is this issuer’s latest earlier reporting period of the same form that was filed before the current report. A previous 10-Q is a different quarter, not a year-over-year comparison. Amendments are excluded.
Compared 57 previous paragraphs and 76 current paragraphs.
49 unchanged; 6 reworded; 21 added; 2 removed; 0 previous and 0 current paragraphs rearranged.
Tables are not compared: 0 previous and 0 current tables excluded. Dates, whitespace, punctuation and numbering changes are ignored; changes to financial figures remain significant.
A changed paragraph is not evidence that risk increased or decreased. An unchanged paragraph does not establish that risk stayed the same.
Added paragraphs (21)
Current report
We may be unable to complete the Crinetics Acquisition, successfully integrate Crinetics’ business, or realize the
Current report
potential commercial benefits of the strategic acquisition, which could adversely affect our business and financial
Current report
Our inability to complete the Crinetics Acquisition or to successfully integrate the Crinetics business could havea
Current report
material adverse effect on our business. The Crinetics Acquisition may not be completed for a number of reasons, including
Current report
the need to satisfy customary closing conditions, the need for antitrust and/or other regulatory approvals, as well as potential
Current report
disputes or litigation that may arise. We provide no assurance that the Crinetics Acquisition will occur or that the closing
Current report
conditions to the Crinetics Acquisition will be satisfied in a timely manner or at all. Our realization of the value from the
Current report
Crinetics Acquisition relies on successful integration of its operations. We may not be able to integrate Crinetics’ business
Current report
successfully into our existing business, make Crinetics’ business profitable, retain key employees or realize anticipated cost
Current report
savings or synergies, if any, from the acquisition, which could adversely affect our business and financial condition. Further,
Current report
our ongoing business may be disrupted, and our management's attention may be diverted by integration activities. In addition,
Current report
the anticipated benefits of the Crinetics Acquisition depend on revenues from PALSONIFY and the commercial potential of
Current report
atumelnant. If PALSONIFY does not achieve the sales, market acceptance, or other commercial performance we expect, if
Current report
development ofatumelnant is delayed or terminated, or if we fail to obtain approval or fail to successfully commercialize
Current report
atumelnant, we may not realize the expected revenue growth or income contribution from these assets on the anticipated
Current report
timeline, or at all, which could adversely affect our business and financial condition.
Current report
•our expectations, plans and anticipated timeline for the pending Crinetics Acquisition, including regarding Crinetics’
Current report
business and operations, the commercial potential of PALSONIFY, and the anticipated potential of atumelnant and
Removed paragraphs (2)
Previous report
have been no material changes from the risk factors previously disclosed in the Annual Report on Form 10-K.
Previous report
expedited basis of six months from the date of FDA acceptance of the BLA;
Reworded paragraphs (6)
Previous wording
Report on Form 10-K for the year ended December 31, 2025, which was filed with the SEC on February 13, 2026. There
Current wording
Report on Form 10-K for the year ended December 31, 2025, which was filed with the SEC on February 13, 2026.
Previous wording
•our ability to continue to launch, commercialize and market our products and our ability to obtain label expansions
Current wording
•our ability to continue to launch, commercialize and market our products, including the anticipated launch of
Previous wording
for existing therapies, including the anticipated launch of povetacicept for the treatment of IgAN;
Current wording
povetacicept for the treatment of IgAN, and our ability to obtain label expansions for existing therapies;
Previous wording
regulatory approval, including our expectations regarding the FDA’s review of the BLA for povetacicept on an
Current wording
regulatory approval, including our expectations regarding the FDA’s review of our BLA for accelerated approval of
Previous wording
•our plans to build and maintain our global supply chains and manufacturing infrastructure and capabilities, including
Current wording
•our plans to maintain and expand our global supply chains and manufacturing infrastructure and capabilities,
Current wording
including for biologics, cell and gene therapies;